Kornimate/medical-research-clean huggingface dataset:
influence of anesthesia methods on ctcs in turbt patients

Conditions: Bladder Cancer

Summary: multiple lines of evidence have shown that anesthesia method is associated with long-term outcomes in patients undergoing surgery due to cancers, including lung, breast, prostate, and bladder cancer, etc. circulating tumor cells (ctcs) have been validated as prognostic biomarkers of a number of cancers. the aim of this study is to investigate the effects of anesthesia methods on the number of ctcs in patients receiving transurethral resection of bladder tumor (turbt). the difference of anesthesia method is achieved by using general anesthesia in one group and spinal anesthesia in the other group.


Eligibility criteria:
inclusion criteria: 1. .≤18 age ≤85，asai-iii. 2. .patients with primary bladder cancer of stage t1 to t4, who are scheduled for transurethral resection of bladder tumor. 3. .written informed consent. exclusion criteria: 1. history of surgery within 6 months. 2. contraindications for spinal anesthesia. 3. with a history of any other malignancy. 4. having received preoperative neoadjuvant therapy. 5. history of long-term opioid use. 6. combined with autoimmune diseases or having a history of prolonged hormone use or immunosuppressant use within 1 year. 7. combined with impaired liver function (child - pugh c) or renal insufficiency (serum creatinine level over 442μmol•l-1). 8. known hypersensitivity or suspected allergy to intervention drugs. 9. proposed postoperative admission to icu.

Keywords: circulating tumor cells general anesthesia spinal anesthesia transurethral resection of bladder tumor
effectiveness of high-intensity laser therapy in de quervain tenosynovitis

Conditions: De Quervain Disease

Summary: 68 de quervain tenosynovitis(mps) diagnosed patients will be randomly divided into 2 groups. to groups; splinting+exercise+high-intensity laser therapy (hilt) and splinting+exercise+sham hilt will be applied. visual anolog scale (vas) scores, quick disabilities of the arm, shoulder, and hand (qdash) questionnaire and hand grip strength measurements of the patients before-after treatment will be recorded and will be evaluated statistically.


Eligibility criteria:
inclusion criteria: * patients diagnosed with unilateral de quervain tenosynovitis 18-65 years old exclusion criteria: * pain history of less than four weeks, * upper extremity entrapment neuropathy, * major psychiatric disease, * upper extremity surgical treatment history, * malignancy history, * chronic rheumatic disease, * cervical radiculopathy, * cervical myelopathy, * local corticosteroid injection prior to de quervain tenosynovitis and receiving physical therapy.

Keywords: hand grip strength high-intensity laser therapy de quervain disease
application of functional renal mri to improve assessment of chronic kidney disease

Conditions: Chronic Kidney Diseases

Summary: research question: can multiparametric renal magnetic resonance imaging (mri) provide structural and functional assessment of the kidneys to deliver prognostic information and guide treatment options in chronic kidney disease (ckd)? aims and objectives: 1. to establish a multiparametric renal mri protocol in ckd cohorts. 2. to use multiparametric mri to characterise people with and without ckd progression. 3. to compare multiparametric renal mri with 'gold-standard' renal biopsy to determine pathological processes of ckd progression that are detectable by mri.

the study will have three stages. stage 1: 45 people with ckd from nine ukrin centres will undergo multiparametric mri to test patient tolerance, data completeness and central data collection processes. stage 2: a multicentre, prospective cohort study of 450 people with ckd, collecting multiparametric renal mri at baseline and 2 years. long-term outcomes will be determined with efficient tracking of kidney failure events via the uk renal registry at 5 and 10 years. stage 3: a mechanistic sub-study of 45 patients (from stage 2) who have had a routine renal biopsy. detailed comparisons will be made between multiparametric mri and histopathological changes. tissue blocks will undergo quantitative analysis of fibrosis, capillary density and inflammation using immunohistochemistry techniques.

Eligibility criteria:
inclusion criteria * age 18-75 years * ckd category g3-4 or ckd category g1-2 with overt albuminuria (urine acr\>30mg/mmol) * capable of giving informed consent exclusion criteria * autosomal dominant polycystic kidney disease (adpkd) * glomerulonephritis (gn) actively receiving immunosuppression, or within the preceding 90 days. * multiple myeloma (mm) * acute kidney injury (aki) within the preceding 90 days * solid organ transplant * known single kidney * contraindications to mri (e.g. permanent pacemaker, metallic foreign bodies, claustrophobia etc.)
pain's treatment with virtual reality in hemodialysis

Conditions: Chronic Pain; Chronic Kidney Diseases

Summary: pain is a frequent and difficult to treat symptom in patients with advanced kidney disease undergoing hemodialysis. pharmacokinetics and pharmacodynamics have complex pharmacokinetics and pharmacodynamics in these types of patients, so non-pharmacological therapies could be very useful. in this project the investigators propose to test whether the use of a virtual reality platform, designed by the company psious and tested in other clinical settings, can reduce the pain that patients experience during connection to the dialysis session. for this the investigators have designed a crossover clinical trial, which will be carried out on 107 hemodialysis patients, in which the intensity of pain (primary objective) and anxiety (secondary objective) that patients experience in the sessions in which participants are treated using virtual reality, it will be compared with the intensity of pain and anxiety experienced by these same patients, in sessions in which the virtual reality platform is not used. the results of this clinical trial can support the use of virtual reality as an adjunctive pain treatment in patients with advanced kidney disease.


Eligibility criteria:
inclusion criteria: * hemodialysis for at least 3 months * pain for for at least 3 months * signature of informed consent exclusion criteria: * pain from a traumatology disease * formal diagnose of dementia
evaluation of effectiveness and safety of xience prime stent (iris-prime)

Conditions: Coronary Artery Disease

Summary: the objective of this study is to evaluate effectiveness and safety of xience prime stent in the "real world" daily practice as compared with other drug eluting stents (dess)

this study is a non-randomized, prospective, open-label registry to compare the effectiveness and safety of xience prime stents versus other dess in patients with coronary artery disease.

Eligibility criteria:
inclusion criteria: * patients receiving xience prime stents. * the patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate institutional review board/ethics committee of the respective clinical site. exclusion criteria: * patients with a mixture of other dess * terminal illness with life expectancy \<1 year * patients presented with cardiogenic shock

Keywords: coronary artery disease requiring drug eluting stents
bariatric surgery in children.

Conditions: Obesity, Morbid

Summary: rationale: in the western world overweight and obesity is an increasing problem both in adults and in children. in youth, it is associated with early death and a number of co-morbidities including metabolic and endocrine changes, increased inflammatory status, cardiovascular abnormalities, nonalcoholic fatty liver disease, and impaired quality of life. the standard treatment for morbid obesity in children is by combined life style interventions. however, the medium and long term effects of dietetic interventions, behaviour therapy and medication is relatively poor. in adults bariatric surgery shows good results with up to 30% weight reduction in 3 years. the preliminary results in youth are similar, but surgery in this age group is relatively uncommon. in the netherlands surgery in this age group is only allowed in clinical trials, until the benefits and risks have been established. (national health authorities) objective: to determine if surgery gives a superior weight and body mass index (bmi) reduction than combined life style interventions in adolescents with morbid obesity and to assess its effect on obesity associated co-morbidity. study design: prospective randomised interventional study. study population: morbidly obese children, aged 14 - 16 years, with sex and age adjusted bmi \>40 kg/m2 or \>35 kg/m2 with co-morbidity. intervention: bariatric surgery by laparoscopic adjustable gastric band (lagb) or combined life style interventions main study parameters/endpoints: primary endpoints: weight loss, loss of excess weight, loss of excess bmi. secondary endpoints: body composition, pubertal development, metabolic and endocrine changes, inflammatory status, cardiovascular abnormalities, non-alcoholic steatohepatitis, brain development, quality of life, and behaviour changes. the potential complications of surgery are monitored.


Eligibility criteria:
inclusion criteria: * aged 14 to 16 * age and sex adjusted bmi \>40 kg/m2 or \>35 kg/m2 with associated co-morbidity. \* associated co-morbidity includes: glucose intolerance, type 2 diabetes, hypertension, pseudotumor cerebri, acanthosis nigricans, obstructive sleep apnoea syndrome, depression, arthropathies, non-alcoholic steatohepatitis and dyslipidemia. * \> 1 year multidisciplinary organized weight reducing attempts with less than 5% weight loss * demonstrate decisional capacity exclusion criteria: * psychologically not suitable * pre-menarche or bone age \<15 years in boys * obesity associated to other disorders such as hypothyroidism * syndromal disorders such as prader-willi syndrome * severe cardiorespiratory impairment (asa class 3 or higher) * insufficiently fluid in the dutch language * unwillingness to adhere to follow-up programmes

Keywords: bariatric surgery adolescent
boosted lexiva with lovaza adjunctive therapy in hypertriglyceridemic, hiv-infected subjects

Conditions: Hypertriglyceridemia; HIV Infection

Summary: in subjects on boosted protease inhibitor (pi)-regimens who have elevated triglycerides, a switch to fosamprenavir/ritonavir once daily followed by the addition of lovaza will result in 30% of patients achieving a reduction in fasting triglycerides \< 200 mg /dl while maintaining virologic suppression.


Eligibility criteria:
inclusion criteria: * fasting triglycerides \>= 200 mg/dl but \<1,200 mg/dl * fasting ldl \<= 160 mg/dl * participation in a lipid-lowering diet and exercise program for at least 28 days * treatment with stable haart consisting of first or second rtv-boosted pi regimen plus optimized background art for at least 3 months * plasma hiv-1 rna \<50 copies/ml * cd4+ cell count \>50 cells/mm3 * male subjection testosterone replacement therapy with total testosterone level \<= 1 x upper limit of normal * female study volunteer must use a form of contraception * ability and willing ness to give written informed consent exclusion criteria: * any grade 4 laboratory abnormality * currently taking amprenavir or fosamprenavir * required a second rtv-boosted pi for reasons of virologic failure * atherosclerotic disease risk * congestive heart failure (nyha class iii or iv) * uncontrolled hypertension * history of pancreatitis * active bleeding disorder * recent history of significant renal, pulmonary, biliary, hepatic or gastrointestinal disease * current diabetes mellitus requiring pharmacological treatment * use of systemic cancer chemotherapy; active cancer * pregnancy or breast-feeding * requirement for any lipid-lowering agent after baseline * use of hormonal anabolic therapies, systemic steroids, immune modulators * use of anticoagulants, investigational antiretroviral drugs * allergy to study drugs * active cdc clinical category c event

Keywords: hiv triglycerides fosamprenavir
comparison of dexmedetomidine and propofol on the delirium and neuroinflammation in patients with sirs.

Conditions: Delirium

Summary: assessment of sedative effects of dexmedetomidine and propofol on the clinical course of delirium and neuroinflammation in patients with sirs using cam-icu scale and protein s100b in serum.


Eligibility criteria:
inclusion criteria: * presence of delirium exclusion criteria: * presence of alzheimer's disease * any mental disorder * presence of cancer
detecting syncope by an integrated multisensor patch-type recorder

Conditions: Syncope, Vasovagal

Summary: the main purpose of this study is to assess the reliability of a new cuffless patch bp monitor in detecting episodes of hypotensive (pre)syncope during tilt testing.

background while ecg monitoring is a reliable and established method that allows to document bradycardia in a substantial proportion of patients affected by cardioinhibitory reflex syncope, the documentation of a transient hypotension is only seldom achieved in patients affected by hypotensive syncope. conventional ambulatory blood pressure (bp) monitoring (abpm) has important limitations due to the short period of monitoring (usually 24-48 hours) and the intermittent nature of bp measurements (usually every 15-20 min). the main purpose of this study is to assess the reliability of a new cuffless patch bp monitor in detecting episodes of hypotensive (pre)syncope. secondary aim regards the estimation of feasibility of this tool. method the study is a prospective intrapatient comparison between bp measured by mean of a cuffless patch bp monitor (rootirx system, rooti labs ltd., taipei, taiwan) and by mean of the standard method during tilt testing. study design bp values observed during tilt testing baseline and at the time of impeding syncope will be measured by mean of the rootirx device and will be compared with the standard of reference. bp will be recorded at rest at baseline, shortly after upright in tilting position (at stabilization), at the time of occurrence of syncope (presyncope) or, alternatively at the time of maximum hypotensive effect, if syncope will not occur, and finally in the recovery period at the end of the test after returning in supine position.

Eligibility criteria:
inclusion criteria: * consecutive patients, * \>18 years of age, * referred for tilt testing because affected by suspected reflex syncope exclusion criteria: * incapability to perform tilt testing

Keywords: syncope tilt table test blood pressure monitoring
denosumab vs zoledronate after lumbar fusion

Conditions: Osteopenia; Lumbar Spondylolisthesis

Summary: the aim of the study was to compare denosumab and zoledronate efficacy in bone mass, bone turnover markers (btms), visual analogue scale (vas) for leg and back, euroqol five-dimension (eq-5d) scores, quality of life questionnaire of the european foundation for osteoporosis-31 (qualeffo-31) scores, and roland-morris disability functioning questionnaire (rmdq) scores, secondary fracture, complications and adverse events after lumbar fusion.

lumbar degenerative disease including spinal stenosis and lumbar spondylolisthesis were the most common reason lead to older patients disability, which was the main indication for older patients to perform lumbar fusion surgery. for patients with lumbar degenerative disease older than 50 years old, a proportion of patients had osteoporosis. the trial aims to investigate whether denosumab versus zoledronate acid in osteopenic patients with lumbar fusion surgery.

Eligibility criteria:
inclusion criteria: * participants aged 40 to 85 years * who diagnosed with lumbar spinal stenosis or lumbar spondylolisthesis * osteopenia with bmd t score between -1 and -2.5 via dual energy x-ray * low back pain or leg numbness or weakness * mri demonstrated signs of nerve compression * patients with one or two level symptoms. exclusion criteria: * cauda equina syndrome * progressive neurologic deficit * history of cancer * scoliosis greater than 15° * back open surgery history * have contraindications for surgery * who had anti-osteoporosis medication within 6 weeks
plasma mexico (plasma mexico)

Conditions: Heart Failure

Summary: collect data on mexican patients diagnosed with heart failure with reduced ejection fraction, their treatments, and their progress in a real-world environment. additional objectives will be analyzed, such as mortality, the use of resources associated with the follow-up of this group of patients and the barriers, if any, to receiving the indicated treatment.

* identify the main epidemiological and clinical characteristics of patients with heart failure with reduced ejection fraction, as well as the medical treatment models used. * determine the prescription rate of a cardiovascular pharmacological treatment and the prescription and implant rate of a cardiac medical device in patients with heart failure with reduced ejection fraction. * determine the mortality rate and its classification in patients with heart failure with reduced ejection fraction. * identify the barriers, if any, to prescribing and implanting a cardiac medical device in those patients with a class i recommendation according to the acc/aha/hrs 2017 guidelines. * determine the population with a profile of 1.5 primary prevention of sudden cardiac death (patients with heart failure in primary prevention who have one or more of the following risk factors: syncope or pre-syncope; left ventricular ejection fraction less than 25%; presence of non-sustained ventricular tachycardia; more than 10 ventricular extrasystoles per hour observed in a 24-hour holter). * collect data on the use of resources associated with the follow-up of patients diagnosed with heart failure with reduced ejection fraction during a period of 12 months to perform a secondary economic analysis.

Eligibility criteria:
inclusion criteria * men and women ≥18 years * patients with heart failure with lvef ≤ 45% will be included * patients must be willing to comply with the study requirements and complete the informed consent form (defined as the legally valid and documented confirmation of a patient's voluntary agreement to participate in the clinical study) exclusion criteria * patients without heart failure or with heart failure with lvef \> 45% * patients unable of comply with the clinical investigation plan * patients who are already enrolled or plan to participate in a concurrent clinical study of any medication and/or device at any time during the course of this clinical study without prior documented approval of the medtronic study manager
rituximab for the treatment of severe ocular manifestations of behcet's disease

Conditions: Behcet's Syndrome

Summary: the purpose of this study is to find if rituximab can improve severe ocular lesions of behcet's disease.

to test in a single blind randomized control study the efficacy of rituximab versus combination of pulse cyclophosphamide and azathioprine. both group receiving 0.5 mg/kg/daily prednisolone.

Eligibility criteria:
inclusion criteria: * behcet's disease fulfilling the new international criteria for behcet's disease * having active ocular lesions (posterior and/or retinal vasculitis) * resistant to cytotoxic drugs + prednisolone 0.5 mg/kg exclusion criteria: * visual acuity less than 1/10 on snellen chart * antecedent of allergic reaction to any component of the therapeutic regimen

Keywords: ocular lesions, visual acuity, retinal vasculitis
ai-guided (genais tm) versus standard physician-guided dietary supplementation for managing metabolic syndrome

Conditions: Metabolic Syndrome

Summary: the study "ai-guided (genais tm) versus standard physician-guided dietary supplementation for managing metabolic syndrome" aimed to compare the effectiveness of ai-guided dietary supplement (ds) prescriptions versus standard physician-guided prescriptions in managing metabolic syndrome. this 6-month randomized controlled trial included 160 participants diagnosed with metabolic syndrome. participants were divided into two groups: one received ds based on physician judgment, and the other based on genais ai system analysis. primary outcomes focused on changes in metabolic parameters, while secondary outcomes included individual components of metabolic syndrome, inflammation levels, body weight, and adherence to the ds regimen. data collection involved genetic, metabolic, and clinical profiling, with ethical considerations ensuring participant confidentiality and informed consent.


Eligibility criteria:
inclusion criteria: * age between 40 and 75 years. * diagnosed with metabolic syndrome, defined by the presence of at least three of the following criteria: * waist circumference \> 102 cm (men) or \> 88 cm (women). * triglycerides ≥ 150 mg/dl. * hdl cholesterol \< 40 mg/dl (men) or \< 50 mg/dl (women). * blood pressure ≥ 130/85 mm hg. * fasting glucose ≥ 100 mg/dl. • willingness to provide genetic and metabolic data. exclusion criteria: * significant renal, hepatic, or cardiovascular diseases. * use of dietary supplements that affect metabolic parameters within the last 3 months. * pregnancy or breastfeeding.

Keywords: ai-guided dietary supplementation metabolic parameters improvement genetic profiling metabolic profiling
evaluate the safety and efficacy of hdm1002 tablets in overweight and obese adults

Conditions: Overweight and Obesity

Summary: it is a multicenter, randomized, double-blind, placebo-controlled phase ii clinical trial to evaluate the safety and efficacy of hdm1002 tablets in overweight and obese adults.

this multicenter, randomized, double-blind, placebo-controlled phase ii clinical trial aims to evaluate the safety and efficacy of hdm1002 tablets in overweight and obese adults. participants with a bmi between 24 and 40 will be include. a total of 180 participants will be randomized in a 1:1:1:1 ratio to receive different doses of hdm1002 or placebo. following the screening period to confirm eligibility up to 2-weeks, the study will consist of a treatment period will be 12 weeks, followed by an approximate 4-week follow-up.

Eligibility criteria:
inclusion criteria: * male or female subjects between 18 and 65 years of age (inclusive). * bmi≥28 but \< 40.0 kg/m2 at screening or randomization，or bmi≥24.0 kg/m2 but \< 28 kg/m2 with any of the following: 1. hypertension 2. impaired fasting glucose or impaired glucose tolerance 3. dyslipidemia 4. obstructive sleep apnea syndrome * at least one previous failure to lose weight through lifestyle modification was defined as \< 5% weight loss after ≥3 months of lifestyle modification. exclusion criteria: * weight change ≥5% as reported or documented. previous diagnosis of type 1, type 2, or any other type of diabetes. * diagnosis of overweight or obesity due to other diseases or medications. * history or family history of medullary thyroid carcinoma, c cell hyperplasia, or multiple endocrine neoplasia type 2. * have diseases or conditions that affect gastric emptying or gastrointestinal absorption of nutrients, such as bariatric surgery or other gastrectomy, irritable bowel syndrome, dyspepsia, chronic pancreatitis, etc. or a history of acute pancreatitis or acute gallbladder disease within 3 months before signing icf. * glp-1r agonist use within 6 months prior to signing icf. * use of hypoglycemic drugs within 3 months before signing icf.

Keywords: hdm1002 tablet overweight and obesity glucagon-like peptide-1 receptor agonists